

## HR 6897

### Synthetic Biology and Active Pharmaceutical Ingredients Act

**Congress:** 118 (2023–2025, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Dec 22, 2023

**Current Status:** Referred to the House Committee on Armed Services.

**Latest Action:** Referred to the House Committee on Armed Services. (Dec 22, 2023)

**Official Text:** <https://www.congress.gov/bill/118th-congress/house-bill/6897>

## Sponsor

**Name:** Rep. Slotkin, Elissa [D-MI-7]

**Party:** Democratic • **State:** MI • **Chamber:** Senate

## Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Gallagher, Mike [R-WI-8]	R · WI		Dec 22, 2023

## Committee Activity

Committee	Chamber	Activity	Date
Armed Services Committee	House	Referred To	Dec 22, 2023

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

No related bills are listed.

## Summary (as of Dec 22, 2023)

### Synthetic Biology and Active Pharmaceutical Ingredients Act

This bill requires the Department of Defense (DOD) to establish a pilot program to support domestic manufacturing of critical pharmaceutical ingredients and their components through certain novel technology.

Specifically, DOD must establish a three-year program that uses technology involving synthetic biology to support domestic manufacturing of pharmaceutical ingredients and related incorporated materials that (1) are not available in a sufficient quantity or quality domestically, and (2) are strategically important to the United States.

## **Actions Timeline**

---

- **Dec 22, 2023:** Introduced in House
- **Dec 22, 2023:** Referred to the House Committee on Armed Services.